AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31926158 — intervention group
Group type: COMPARATOR
Intervention: Routine chest tube drainage (control group)
Number of subjects: 96
Study 31058571 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 68
Study 31058571 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 68
Study 28456090 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCs ≥2 at D0
Number of subjects: 106
Study 28456090 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCs ≥2 at D28
Number of subjects: 106
Study 28456090 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC count groups (low/low, high/low, low-high/high) based on D0 and D28
Number of subjects: 106
Study 26590418 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary intervention based on machine-learning algorithm
Number of subjects: 800
Study 26590418 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 800
Study 22402617 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + DL (scaling, root planing, and diode laser treatment)
Number of subjects: 36
Study 22402617 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing only)
Number of subjects: 36
Study 22402617 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + DL
Number of subjects: 36
Study 22402617 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 36
Study 21784351 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 2528
Study 21784351 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2528
Study 21784351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2528
Study 21784351 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (Naproxen and Celecoxib)
Number of subjects: 2528
Study 19548010 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (Vitrebond)
Number of subjects: 27
Study 19548010 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (Fuji Lining LC)
Number of subjects: 27
Study 19548010 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide cement (Dycal)
Number of subjects: 27
Study 16449338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortistatin-17
Number of subjects: 0
Study 16449338 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin-14
Number of subjects: 0
Study 16449338 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 15229915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound dating at 12-14 weeks
Number of subjects: 363
Study 15229915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound dating at 15-20 weeks
Number of subjects: 363
Study 15229915 — intervention group
Group type: EXPERIMENTAL
Intervention: Three dating formulae
Number of subjects: 363
Study 15229915 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dating formulae
Number of subjects: 363
Study 15229915 — intervention group
Group type: EXPERIMENTAL
Intervention: Five dating formulae
Number of subjects: 363
Study 15229915 — intervention group
Group type: EXPERIMENTAL
Intervention: Early scanning
Number of subjects: 363
Study 15229915 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean true gestational age at delivery in IVF pregnancies
Number of subjects: 363
Study 11596834 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care (including zolmitriptan)
Number of subjects: 0
Study 11596834 — intervention group
Group type: COMPARATOR
Intervention: Stepped care
Number of subjects: 0
Study 9466100 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg kg‐1
Number of subjects: 30
Study 9466100 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 30
Study 7933026 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography at proximal location
Number of subjects: 47
Study 7933026 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography at distal location
Number of subjects: 47
Study 3351267 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 575
Study 3351267 — intervention group
Group type: COMPARATOR
Intervention: povidone‐iodine solution
Number of subjects: 575
Study 3351267 — intervention group
Group type: COMPARATOR
Intervention: medicated bar soap
Number of subjects: 575
Study 29385024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong Improvements through Fitness Together (LIFT)
Number of subjects: 113
Study 29385024 — intervention group
Group type: COMPARATOR
Intervention: Stay Strong; Stay Healthy (SSSH)
Number of subjects: 113
Study 27716209 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (10-weekly intramuscular injections for 56 weeks)
Number of subjects: 100
Study 27716209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24157087 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Motivational Intervention (FMI)
Number of subjects: 97
Study 24157087 — intervention group
Group type: COMPARATOR
Intervention: Routine Family Support (RFS)
Number of subjects: 97
Study 22462423 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 300
Study 22462423 — intervention group
Group type: COMPARATOR
Intervention: DMARD + MTX
Number of subjects: 300
Study 21353106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/d)
Number of subjects: 240
Study 21353106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 18027048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (group 2)
Number of subjects: 30
Study 18027048 — intervention group
Group type: COMPARATOR
Intervention: Normal patients without SCD (control group, group 1)
Number of subjects: 30
Study 16680957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FE enzymes (50 ml dissolved in 0‐150 ml normal saline to reach the final concentration of 1‐3 U/ml)
Number of subjects: 30
Study 16680957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FE enzymes
Number of subjects: 30
Study 16680957 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 30
Study 12503230 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Empowerment and Nutrition Program (CENP)
Number of subjects: 240
Study 12503230 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 240
Study 9504644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 300
Study 9504644 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen-progesterone combinations
Number of subjects: 300
Study 9504644 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen monotherapy
Number of subjects: 300
Study 7991068 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP) 100 micrograms
Number of subjects: 22
Study 7991068 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine methionine (PHM) 100 micrograms
Number of subjects: 22
Study 3052668 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner intervention with advice and information on reducing alcohol consumption, including a drinking diary.
Number of subjects: 909
Study 30714689 — intervention group
Group type: EXPERIMENTAL
Intervention: System-based intervention including a real-time warning system, race-specific feedback, and a nurse navigator.
Number of subjects: 360
Study 30714689 — intervention group
Group type: COMPARATOR
Intervention: Retrospective control group
Number of subjects: 360
Study 28183036 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp block
Number of subjects: 47
Study 28183036 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration (bupivacaine 0.5%)
Number of subjects: 47
Study 28183036 — intervention group
Group type: COMPARATOR
Intervention: Control (remifentanil)
Number of subjects: 47
Study 23432894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (change of positioning and stimulation of cough)
Number of subjects: 42
Study 21828339 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast (Day BL)
Number of subjects: 12
Study 21828339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch after breakfast (Day BL)
Number of subjects: 12
Study 21828339 — intervention group
Group type: COMPARATOR
Intervention: Lunch without breakfast (Day FL)
Number of subjects: 12
Study 21828339 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and C-peptide response
Number of subjects: 12
Study 21828339 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 12
Study 19126625 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg HPLC‐purified DHEA/d orally for 12 months
Number of subjects: 23
Study 19126625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17124720 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaPep277 (1 mg)
Number of subjects: 35
Study 17124720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17124720 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaPep277
Number of subjects: 35
Study 17124720 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaPep277 (after extension)
Number of subjects: 35
Study 17124720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after extension)
Number of subjects: 35
Study 14984446 — intervention group
Group type: EXPERIMENTAL
Intervention: Church-based diabetes risk reduction programme
Number of subjects: 516
Study 11881266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation and Distress of Pain Visual Analogue Scales (VAS)
Number of subjects: 0
Study 11881266 — intervention group
Group type: COMPARATOR
Intervention: Dual numerical rating scales (NRS)
Number of subjects: 0
Study 9609376 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE membranes
Number of subjects: 15
Study 9609376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose membranes
Number of subjects: 15
Study 7811056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg
Number of subjects: 7
Study 7811056 — intervention group
Group type: COMPARATOR
Intervention: Dapsone 100 mg with 30 ml high potency antacid
Number of subjects: 7
Study 2809052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding treatment (hourly checks, asking for toileting assistance, social reinforcement)
Number of subjects: 126
Study 2809052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding treatment
Number of subjects: 126
Study 31971279 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS) applied to the lumbar region for 10 minutes (frequency, 1 MHz; intensity, 1.5 W/cm2; effective irradiation area of the transducer head, 5 cm2)
Number of subjects: 40
Study 31971279 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy modalities (superficial heating and transcutaneous electrical nerve stimulation) and exercise therapy
Number of subjects: 40
Study 30585257 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FOLFIRI (irinotecan dose 300 mg/m2 for UGT1A1*1/*1 and 260 mg/m2 for *1/*28)
Number of subjects: 82
Study 30585257 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan dose 180 mg/m2)
Number of subjects: 82
Study 30585257 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FOLFIRI
Number of subjects: 82
Study 30585257 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 82
Study 30585257 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FOLFIRI and FOLFIRI
Number of subjects: 82
Study 28243021 — intervention group
Group type: EXPERIMENTAL
Intervention: modified L‐haptic IOL
Number of subjects: 150
Study 28243021 — intervention group
Group type: EXPERIMENTAL
Intervention: modified C‐haptic IOL
Number of subjects: 150
Study 28243021 — intervention group
Group type: EXPERIMENTAL
Intervention: plate‐haptic IOL
Number of subjects: 150
Study 28243021 — intervention group
Group type: COMPARATOR
Intervention: All IOLs
Number of subjects: 150
Study 25980699 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Cardiac Rehabilitation Program (vCRP)
Number of subjects: 22
Study 24804018 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Wellmune WGP(R) beta‐1,3/1,6‐Glucan daily for 4 weeks
Number of subjects: 48
Study 24804018 — intervention group
Group type: COMPARATOR
Intervention: 250 mg placebo (rice flour) daily for 4 weeks
Number of subjects: 48
Study 22068444 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sport activity during the school day (1 hour of regulated sport exercise, including 15 min of endurance training, five days a week)
Number of subjects: 232
Study 22068444 — intervention group
Group type: COMPARATOR
Intervention: Customary sport activity (two hours a week)
Number of subjects: 232
Study 22068444 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sport activity during the school day
Number of subjects: 232
Study 19935991 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous adhesiolysis with targeted delivery and injection of lidocaine, 10% hypertonic sodium chloride solution, and non‐particulate Betamethasone.
Number of subjects: 50
Study 19935991 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural injections with catheterization up to S3 with local anesthetic, 0.9% sodium chloride solution, non‐particulate betamethasone.
Number of subjects: 50
Study 16467120 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 16467120 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 16467120 — intervention group
Group type: COMPARATOR
Intervention: Combination of Anastrozole and Tamoxifen
Number of subjects: 0
Study 15936866 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opiate antagonist)
Number of subjects: 0
Study 15936866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12496531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductal occlusion with fibrin glue
Number of subjects: 182
Study 12496531 — intervention group
Group type: COMPARATOR
Intervention: No ductal occlusion (control)
Number of subjects: 182
Study 10636456 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin (40 mg once daily)
Number of subjects: 157
Study 10636456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 7777109 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 micrograms/day)
Number of subjects: 13
Study 7777109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2131899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine administered at doses of 10 mg/h, 12.5 mg/h, and 15.0 mg/h for 5 minutes, 5 minutes, and 15 minutes, respectively.
Number of subjects: 7
Study 2131899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine during maintenance period at an infusion rate reduced to 3.0 mg/h, adjusted by 1.0 to 2.5 mg/h every 15 minutes as needed.
Number of subjects: 7
Study 2131899 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of plasma norepinephrine (NE) concentrations prior to nicardipine infusion.
Number of subjects: 7
Study 2131899 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine treatment.
Number of subjects: 7
Study 355601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 1200 mg daily
Number of subjects: 12
Study 355601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31630899 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 90
Study 31630899 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study 30878623 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth augmented social support training (daily text-messages that synchronize with the patient messages)
Number of subjects: 166
Study 30878623 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet based training (same content mailed to their house)
Number of subjects: 166
Study 30878623 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth augmented social support training
Number of subjects: 166
Study 30878623 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet based training
Number of subjects: 166
Study 29188878 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/week brisk walking program for six months (n=61)
Number of subjects: 121
Study 29188878 — intervention group
Group type: COMPARATOR
Intervention: Control group with physical activity allowed freely (n=60)
Number of subjects: 121
Study 25965641 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft liner with silver zeolite (SZ)
Number of subjects: 30
Study 25965641 — intervention group
Group type: COMPARATOR
Intervention: Soft liner without silver zeolite (S)
Number of subjects: 30
Study 24273967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medical treatment (Shen invigorating and blood activating, Shen invigorating and Pi supplementing, Shen‐qi benefiting)
Number of subjects: 128
Study 24273967 — intervention group
Group type: COMPARATOR
Intervention: Western medical treatment (Clomifene, 25 mg per day)
Number of subjects: 128
Study 21574782 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol by filmstrip
Number of subjects: 43
Study 21574782 — intervention group
Group type: COMPARATOR
Intervention: 400 IU cholecalciferol by dropper (1 mL syrup)
Number of subjects: 43
Study 19619896 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 682
Study 16723246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood with hot shot (CB+HS)
Number of subjects: 103
Study 16723246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood (CB)
Number of subjects: 103
Study 16723246 — intervention group
Group type: COMPARATOR
Intervention: Intermittent antegrade cold crystalloid (CC)
Number of subjects: 103
Study 15257742 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) used in regenerative periodontal surgery
Number of subjects: 166
Study 11216500 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran biscuit (7.5 g/day) for 12 weeks
Number of subjects: 12
Study 11216500 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran biscuit (15 g/day) for 12 weeks
Number of subjects: 12
Study 9328383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini‐Stetten repair for group I (firm posterior wall)
Number of subjects: 365
Study 9328383 — intervention group
Group type: COMPARATOR
Intervention: Ring narrowing for group I (firm posterior wall)
Number of subjects: 365
Study 9328383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini‐Stetten repair for group II (weakened posterior wall)
Number of subjects: 365
Study 9328383 — intervention group
Group type: COMPARATOR
Intervention: Shouldice repair for group II (weakened posterior wall)
Number of subjects: 365
Study 8222484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 9
Study 8222484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 4038159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15 g daily for 4 weeks)
Number of subjects: 20
Study 4038159 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil supplement (15 g daily for 4 weeks)
Number of subjects: 20
Study 30851442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 450 mg with food
Number of subjects: 306
Study 30851442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 600 mg with food
Number of subjects: 306
Study 30851442 — intervention group
Group type: COMPARATOR
Intervention: Ceritinib 750 mg fasted
Number of subjects: 306
Study 28805780 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (Thoracic Epidural Anesthesia)
Number of subjects: 300
Study 28805780 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB (Paravertebral Blockade)
Number of subjects: 300
Study 28805780 — intervention group
Group type: EXPERIMENTAL
Intervention: ICB (Intercostal Blockade)
Number of subjects: 300
Study 24814892 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of PepGen P‐15® and OsteoGraf®/N‐700 (test group)
Number of subjects: 24
Study 24814892 — intervention group
Group type: COMPARATOR
Intervention: BioOss® (control group)
Number of subjects: 24
Study 24301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-face injections of abobotulinum toxin A (ABO) at doses of 120-165 U
Number of subjects: 90
Study 24301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-face injections of abobotulinum toxin A (ABO) at doses of 166-205 U
Number of subjects: 90
Study 24301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-face injections of abobotulinum toxin A (ABO) at doses of 206-250 U
Number of subjects: 90
Study 22080324 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (2.5 g mixed in 500 ml of Gatorade®)
Number of subjects: 0
Study 22080324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 ml of Gatorade®)
Number of subjects: 0
Study 19878590 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (400/12 microg)
Number of subjects: 55
Study 19878590 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone (50/500 microg)
Number of subjects: 55
Study 17121555 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60
Study 17121555 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 60
Study 14691990 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-g needle
Number of subjects: 100
Study 14691990 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL syringe
Number of subjects: 100
Study 14691990 — intervention group
Group type: COMPARATOR
Intervention: 20-g needle
Number of subjects: 100
Study 14691990 — intervention group
Group type: COMPARATOR
Intervention: 5-mL syringe
Number of subjects: 100
Study 11425979 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic, contrast-enhanced, multi-detector row CT during the pancreatic parenchymal phase (PPP)
Number of subjects: 77
Study 11425979 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic, contrast-enhanced, multi-detector row CT during the portal venous phase (PVP)
Number of subjects: 77
Study 11425979 — intervention group
Group type: COMPARATOR
Intervention: Multiphasic, contrast-enhanced, multi-detector row CT during the arterial phase (AP)
Number of subjects: 77